AMZN
Amazon.com, Inc.
AMZN has the edge over CVSA overall, supported by stronger valuation and stronger modeled upside.
CVSA
Covista Inc.
CVSA offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
CVSA Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Healthy |
CVSA's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN has the edge over CVSA in the historical PE scenario, which offers more potential upside but is not a forecast.
CVSA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6x | $44.17 | -63% |
| Forward | 13x | $119 | — |
| Current | 16x | $119 | — |
| Fair | 18x | $135 | +14% |
| Expensive | 24x | $173 | +46% |
Historical ranges are pointers, not guarantees.
CVSA's PE is in its fair range at 16x. If earnings grow as analysts expect, today's price would be 13x next year's earnings, in its cheap range.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
CVSA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
CVSA has the edge over AMZN on the outlook, with more favorable valuation expectations.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over CVSA on earnings, with stronger typical year-over-year growth.
CVSA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.18 | +25% |
| Q3 2026 | $7.32 | +9.7% |
| Q2 2026 | $7.04 | +14% |
| Q1 2026 | $6.41 | +7.2% |
| Q4 2025 | $6.80 | +28% |
| Q3 2025 | $6.67 | +54% |
| Q2 2025 | $6.18 | +82% |
| Q1 2025 | $5.98 | +127% |
| Q4 2024 | $5.32 | +96% |
CVSA's earnings per share have climbed steadily: $7.32 over the past year, up 9.7% from the year before, and higher year over year for 11 quarters in a row.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over CVSA on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN's operating margin was 14% last quarter, up 4.2 points from the same quarter a year ago, near the top of its range since 2019.
CVSA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $511.5M | +11% |
| Q2 2026 | $501.4M | +9.7% |
| Q1 2026 | $487M | +4.5% |
| Q4 2025 | $503.4M | +12% |
| Q3 2025 | $462.3M | +11% |
| Q2 2025 | $457.1M | +12% |
| Q1 2025 | $466.1M | +13% |
| Q4 2024 | $447.7M | +14% |
CVSA's revenue has grown year over year for 15 quarters in a row: $512M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 19% | +0.7 points |
| Q2 2026 | 19% | +2.2 points |
| Q1 2026 | 19% | -0.7 points |
| Q4 2025 | 22% | -1.1 points |
| Q3 2025 | 18% | +1.7 points |
| Q2 2025 | 17% | +0.1 points |
| Q1 2025 | 19% | +4.5 points |
| Q4 2024 | 23% | +8.3 points |
CVSA has the edge over AMZN on profitability, with a higher operating margin.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
CVSA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $76.4M | -33% |
| Q2 2026 | $97.1M | +139% |
| Q1 2026 | $165.9M | -16% |
| Q4 2025 | $15.1M | +$44.8M |
| Q3 2025 | $114.5M | +45% |
| Q2 2025 | $40.7M | -6.8% |
| Q1 2025 | $197.7M | +40% |
| Q4 2024 | -$29.7M | -$7.3M |
CVSA has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
CVSA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -3.2% | -1.1M shares |
| 1 year | -6.7% | -2.5M shares |
| 3 years | -18% | -7.6M shares |
| 5 years | -30% | -15.1M shares |
| Available history | -36% | -19.5M shares |
CVSA has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $81M |
| Q2 2026 | — |
| Q1 2026 | $67.5M |
| Q4 2025 | $164.8M |
| Q3 2025 | $7.6M |
| Q2 2025 | $66.7M |
| Q1 2025 | $72.4M |
| Q4 2024 | $40.9M |
CVSA spent $313M buying back its own shares over the past year, up 67% from the year before.
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
CVSA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.6x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.8x | Very low |
| Q4 2025 | 1.1x | Healthy |
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 0.9x | Very low |
| Q4 2024 | 1.2x | Healthy |
CVSA has the edge over AMZN on leverage, with a lower net debt burden relative to earnings.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
CVSA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.3 | Neutral |
| Stochastic | 24.4 | Neutral |
CVSA's weekly RSI is 47 (neutral) and its Stochastic is 24 (neutral).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
CVSA PE vs Consumer Cyclical Sector
| Metric | CVSA | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 18x | 9.8% below |
| PE % | 33 | 47 | 14 pts below |
CVSA has the edge over AMZN on valuation relative to its sector.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over CVSA on trend strength, trading above more of its moving averages.
CVSA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $123.5 | 3.6% below |
| 20 week MA | $126.4 | 5.8% below |
| 50 week MA | $117.5 | 1.3% above |
| 100 week MA | $116.5 | 2.2% above |
| 200 week MA | $85.9 | 39% above |
CVSA has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 39% above its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over CVSA on returns for 2026, with the stronger performance.
CVSA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.0 | $34.4 | -1.8% |
| 2021 | $34.4 | $30.0 | -13% |
| 2022 | $30.0 | $36.2 | +20% |
| 2023 | $36.2 | $59.0 | +63% |
| 2024 | $59.0 | $90.9 | +54% |
| 2025 | $90.9 | $104.7 | +15% |
| 2026 YTD | $104.7 | $119.0 | +14% |
CVSA has finished higher in four of the last six years, two of them by more than 50%. It's up 14% so far in 2026.